Urinary obstruction in prostate cancer patients from the dutch trial (68 Gy vs. 78 Gy): Relationships with local dose, acute effects, and baseline characteristics
Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer
A. Al-Mamgani, W.L. van Putten, and W.D. Heemsbergen Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 980 988
Incidence of urethral stricture after primary treatment for prostate cancer: Data from CaPSURE
S.P. Elliott, M.V. Meng, and E.P. Elkin Incidence of urethral stricture after primary treatment for prostate cancer: Data from CaPSURE J Urol 178 2007 529 534
Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive 3D conformal RT: Dose-volume analysis of a Phase III dose-escalation study
A. Harsolia, C. Vargas, and D. Yan Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive 3D conformal RT: Dose-volume analysis of a Phase III dose-escalation study Int J Radiat Oncol Biol Phys 69 2007 1100 1109
Acute and late complications after radiotherapy for prostate cancer: Results of a multi-center randomized trial comparing 68 Gy with 78 Gy
S.T.H. Peeters, W.D. Heemsbergen, and W.L. van Putten Acute and late complications after radiotherapy for prostate cancer: Results of a multi-center randomized trial comparing 68 Gy with 78 Gy Int J Radiat Oncol Biol Phys 61 2005 1019 1043
Long-term urinary toxicity after 3D CRT for prostate cancer in patients with prior history of TURP
A.S. Sandhu, M.J. Zelefsky, and H.J. Lee Long-term urinary toxicity after 3D CRT for prostate cancer in patients with prior history of TURP Int J Radiat Oncol Biol Phys 48 2000 643 647
Late GI morbidity after 3D-CRT for prostate cancer fades with time in contrast to GU morbidity
A. Karlssdottir, L.P. Muren, and T. Wentzel-Larsen Late GI morbidity after 3D-CRT for prostate cancer fades with time in contrast to GU morbidity Int J Radiat Oncol Biol Phys 70 2008 1478 1486
Absolute and relative dose-surface and dose-volume histograms of the bladder; Which one is the most invariant under bladder filling changes?
M.S. Hoogeman, S.T.H. Peeters, and J. De Bois Absolute and relative dose-surface and dose-volume histograms of the bladder; which one is the most invariant under bladder filling changes? Phys Med Biol 50 2005 3589 3597
Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer
M.R. Cheung, S.L. Tucker, and L. Dong Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 67 2007 1059 1065
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomized controlled trial
D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomized controlled trial Lancet Oncol 8 2007 475 487
Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer
D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
Toxicity after 3D radiotherapy for prostate cancer on RTOG 9406 dose level v
J.M. Michalski, K. Winter, and J.A. Purdy Toxicity after 3D radiotherapy for prostate cancer on RTOG 9406 dose level V Int J Radiat Oncol Biol Phys 62 2005 706 713